Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Sustiva (Efavirenz) in New Formulation

February 8, 2002

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

The Food and Drug Administration approved on February 1, 2002, a new formulation of Sustiva (efavirenz). Sustiva is a once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination treatment for HIV. The new formulation will provide physicians with the option to prescribe one 600 mg Sustiva tablet once daily instead of three 200 mg capsules once daily (as Sustiva has been used since it was approved in September 1998). The manufacturer indicates that the 600 mg tablet is approximately the same size as one Sustiva 200 mg capsule.

Bristol-Myers Squibb Virology believes that the new tablet formulation of Sustiva will help reduce the number of pills people living with HIV have to take. The 600 mg tablet formulation will be available in late February. Bristol-Myers Squibb Virology will continue to manufacture the 200 mg capsules for those who still wish to take Sustiva as three capsules once-daily as part of their combination regimen.

Including the changes in the drug formulation, Bristol-Myers Squibb Virology included new statements in the package insert to be reflective of the NNRTI. The changes in the package insert reflect drug interactions, adverse event information, and precautions.

Note: Sustiva should still not be taken with Hismanal® (astemizole), Propulsid® (cisapride), Versed® (midazolam), Halcion® (triazolam) or ergot derivatives. Sustiva drug interaction information includes the following medications and herbs: St. John's wort, lorazepam, methadone, cetirizine and rifabutin.

Advertisement
To review the revised label insert: www.fda.gov/cder/foi/label/2002/21360lbl.pdf (PDF).


A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.
 
See Also
More on HIV Medications
More News on Efavirenz (Sustiva, Stocrin)

Tools
 

Advertisement